Sugi Predict

Sugi Predict / Compounds / SCHEMBL2734801

SCHEMBL2734801

SCHEMBL2734801

Cc1[nH]c2cc[c]cc2c1C(N)=O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NR4A2 P43354 1/20 0.40
▸ ALDH1A1 P00352 7/20 0.39
▸ RAB9A P51151 6/20 0.39
▸ KMT2A Q03164 5/20 0.39
▸ LMNA P02545 5/20 0.39
▸ MITF O75030 2/20 0.39
▸ NPSR1 Q6W5P4 1/20 0.39
▸ MAPT P10636 9/20 0.35
▸ NPC1 O15118 5/20 0.35
▸ GAA P10253 4/20 0.35
▸ MEN1 O00255 2/20 0.35
▸ HTT P42858 2/20 0.35
▸ CYP1A2 P05177 1/20 0.35
▸ CYP3A4 P08684 1/20 0.35
▸ CYP2D6 P10635 1/20 0.35
▸ CYP2C9 P11712 1/20 0.35
▸ CYP2C19 P33261 1/20 0.35
▸ PKM P14618 2/20 0.35
▸ HSD17B10 Q99714 1/20 0.35
▸ KDM4E B2RXH2 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4882865 0.87 NR4A2 (0.40) NR4A2ALDH1A1RAB9AKMT2ALMNA
SCHEMBL3483291 0.87 NR4A2 (0.41) NR4A2ALDH1A1RAB9AKMT2ALMNA
SCHEMBL5670227 0.77 MAP2 (0.40) ALDH1A1RAB9AKMT2AMAPTNPC1
SCHEMBL3624515 0.76 NR4A2 (0.65) NR4A2ALDH1A1RAB9AKMT2ALMNA
SCHEMBL314742 0.73 AHR (0.52) ALDH1A1RAB9ALMNAMAPTNPC1
SCHEMBL3628074 0.71 MAP2 (0.50) LMNAMAPTGAAJAK2SMN1; SMN2
SCHEMBL3482936 0.70 ALDH1A1 (0.48) ALDH1A1KMT2ANPSR1MAPTGAA
SCHEMBL3482830 0.70 ALDH1A1 (0.44) ALDH1A1KMT2AMAPTGAAMEN1
SCHEMBL30523119 0.69 ALDH1A1 (0.65) ALDH1A1RAB9AKMT2AMAPTNPC1
SCHEMBL2790758 0.68 POLB (0.52) ALDH1A1LMNAGAAHTTCYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1904439-B1 SPHINGOSINE KINASE INHIBITORS APOGEE BIOTHECHNOLOGY CORP (US) 2014-11-26 — — EP claimed
US-8557800-B2 Sphingosine kinase inhibitors APOGEE BIOTECHNOLOGY CORPORATION (US) 2013-10-15 — — US claimed
EP-1773768-A4 PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS EXELIXIS INC (US) 2008-08-06 — — EP claimed
EP-1904439-A2 SPHINGOSINE KINASE INHIBITORS Apogee Biothechnology Corporation (US) 2008-04-02 — — EP claimed
EP-1773768-A2 PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS Exelixis, Inc. (US) 2007-04-18 — — EP claimed
WO-2006138660-A2 SPHINGOSINE KINASE INHIBITORS APOGEE BIOTECHNOLOGY CORPORATION (US) 2006-12-28 — — WO claimed
US-20060287317-A1 SPHINGOSINE KINASE INHIBITORS APOGEE BIOTECHNOLOGY CORPORATION (US) 2006-12-21 — — US claimed
WO-2006012642-A2 PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS EXELIXIS, INC. (US) 2006-02-02 — — WO claimed
US-RE49811-E1 Sphingosine kinase inhibitors APOGEE BIOTECHNOLOGY CORPORATION (US) 2024-01-23 — — US disclosed
EP-3407912-B1 METHODS FOR ENHANCING THE POTENCY OF THE IMMUNE CHECKPOINT INHIBITORS INST NAT SANTE RECH MED (FR) 2022-05-18 — — EP disclosed
US-20210040215-A1 METHODS FOR ENHANCING THE POTENCY OF THE IMMUNE CHECKPOINT INHIBITORS Université Toulouse III - Paul Sabatier (FR) 2021-02-11 — — US disclosed
US-10822415-B2 Methods for enhancing the potency of the immune checkpoint inhibitors INSERM (INSTITUT NATIONAL DE LA SANTÉET DE LA RECHERCHE MÉDICALE) (FR) 2020-11-03 — — US disclosed
US-20190031757-A1 METHODS FOR ENHANCING THE POTENCY OF THE IMMUNE CHECKPOINT INHIBITORS INSERM (Institut National de la Santé et de la Recherche Médicale (FR) 2019-01-31 — — US disclosed
EP-3407912-A1 METHODS FOR ENHANCING THE POTENCY OF THE IMMUNE CHECKPOINT INHIBITORS INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) 2018-12-05 — — EP disclosed
EP-1844020-A1 HETEROCYCLIC CARBOXAMIDE COMPOUNDS AS STEROID NUCLEAR RECEPTOR LIGANDS Exelixis, Inc. (US) 2007-10-17 — — EP disclosed
EP-1773768-A2 PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS Exelixis, Inc. (US) 2007-04-18 — — EP disclosed
WO-2006138660-A2 SPHINGOSINE KINASE INHIBITORS APOGEE BIOTECHNOLOGY CORPORATION (US) 2006-12-28 — — WO disclosed
US-20060287317-A1 SPHINGOSINE KINASE INHIBITORS APOGEE BIOTECHNOLOGY CORPORATION (US) 2006-12-21 — — US disclosed
WO-2006076202-A1 HETEROCYCLIC CARBOXAMIDE COMPOUNDS AS STEROID NUCLEAR RECEPTORS LIGANDS EXELIXIS, INC. (US) 2006-07-20 — — WO disclosed
WO-2006012642-A2 PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS EXELIXIS, INC. (US) 2006-02-02 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060287317-A1 SPHINGOSINE KINASE INHIBITORS SPHK1, SPHK2, S1PR1 NR4A2 3910/4885ALDH1A1 2654/4885RAB9A 2364/4885
US-20190031757-A1 METHODS FOR ENHANCING THE POTENCY OF THE IMMUNE CHECKPOINT INHIBITORS CD274, PDCD1, PDCD1LG2 NR4A2 2615/4885ALDH1A1 2136/4885RAB9A 3023/4885
US-20210040215-A1 METHODS FOR ENHANCING THE POTENCY OF THE IMMUNE CHECKPOINT INHIBITORS CD274, PDCD1, PDCD1LG2 NR4A2 2615/4885ALDH1A1 2136/4885RAB9A 3023/4885
US-10822415-B2 Methods for enhancing the potency of the immune checkpoint inhibitors CD274, PDCD1, PDCD1LG2 NR4A2 2615/4885ALDH1A1 2136/4885RAB9A 3023/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.